EVISA Print | Glossary on | Contact EVISA | Sitemap | Home   
 Advanced search
The establishment of EVISA is funded by the EU through the Fifth Framework Programme (G7RT- CT- 2002- 05112).


Supporters of EVISA includes:

Chromium (III) - not only therapeutic?

(23.11.2004)


Chromium is often cited as one element, showing extremely different biological effects depending on its valency state. While the Cr(III) species are considered essential for playing an important role in fat and glucose metabolism, Cr(VI) species have been identified as being toxic, causing cancer and DNA damage.

Cr(III) compounds are reported to have insulin-enhancing properties attributed to specific interactions with cellular insulin receptors. Unfortunately, the enhancing species containing chromium (Chromodulin) could not yet been isolated and identified. Anyhow, because of the reported beneficial effects, Cr(III) componds are often added to food supplements and total parenteral nutrition as a dietary supplement mostly in the form of its picolinate or nicotinate.

The Australian researchers focused their work on a well-characterized trinuclear oxo–carboxylato complex, [Cr(III)3O(CO2ET)6(OH2)3]+, named here as 'Complex A', which has been proposed as a structural and functional mimetic of chromodulin and a safer potential therapeutic agent than picolinate or nicotinate. The oxidation of this compound using H2O2 and ClO- under conditions similar to those found in the body was followed by using EPR spectra analysis which clearly indicated the formation of Cr(VI) compounds.

Tests on rats using Complex A, compared against tests using an alternative treatment with [Cr(III)(pic)3] ('Complex B'), showed that only Complex A worked as an efficient insulin activator. Since Complex A is also more easily oxidised than Complex B, this indicates that Cr(VI) production is involved in such activation.

The researchers conclude, that the ease of oxidation of Complex A to carcinogenic Cr(VI) under biologically relevant conditions warrants further research into the safety of using any Cr(III) compound as a nutritional supplement or therapeutic agent.

Michael Sperling


Original article:

 Irma Mulyani, Aviva Levina, A. Lay, Biomimetic Oxidation of Chromium(iii): Does the Antidiabetic Activity of Chromium(iii) Involve Carcinogenic Chromium(vi)?, Angew. Chem., 43/34 (2004) 4504-4507. DOI: 10.1002/anie.200460113


Related studies (newest first):

Aviva Levina, Peter A. Lay, Chemical Properties and Toxicity of Chromium(III) Nutritional Supplements, Chem. Res. Toxicol. 2008, 21, 563–571. doi: 10.1021/tx700385t

Maria A. Andersson, Kierstin V. Petersson Grawe, Oskar M. Karlsson, Lilianne A.G. Abramsson-Zetterberg, Björn E. Hellman, Evaluation of the potential genotoxicity of chromium picolinate in mammalian cells in vivo and in vitro, Food Chem. Toxicol., 45 (2007) 1097–1106. doi:10.1016/j.fct.2006.11.008

 

 Related EVISA resources:

Link database: Chromium as an essential nutrient
Link database: ATSDR: Toxicological Profile for Chromium
Link database: More about Cr(III)/Cr(VI)


 Related News

 Nutra Ingredients: Nutrition 21 maintains turnaround in “significant quarter”
 Medscape Aug. 29, 2003: Chromium Supplements Appear to Improve Glucose Sensitivity in Diabetics
 Medscape Sept. 3, 2004: Low Chromium Linked to Heart Disease Risk in Patients With Diabetes
 LOS ANGELES--(BUSINESS WIRE)--Feb. 15, 2005--New Chromium Supplementation Clinical Trial Initiated
 
Medscape March 1, 2005: Chromium Supplementation May Not Improve Impaired Glucose Tolerance
 EVISA News, March 20, 2005: United Kingdom's Food Standards Agency granted derogation to Chromium(III) compounds as a food supplement


last time modified December 9, 2013




Comments






Imprint     Disclaimer

© 2003 - 2010 by European Virtual Institute for Speciation Analysis ( EVISA )